SNF Platform Study of HR+/ HER2-advanced Breast Cancer

This study is an umbrella trial for women with advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative, whose cancer progressed after prior treatment with CDK4/6 inhibitors (a common targeted therapy). It tests various drug combinations tailored to each patient's tumor profile. **You may be eligible if...** - You are a woman 18 years or older - You have HR+/HER2- breast cancer confirmed by biopsy (hormone receptor-positive, HER2-negative) - Your cancer has spread locally or to other organs and cannot be surgically cured - Your cancer progressed on or after treatment with a CDK4/6 inhibitor drug **You may NOT be eligible if...** - You received chemotherapy or immunotherapy within the last 3 weeks - You have uncontrolled brain metastases - You have a history of serious heart disease Talk to your doctor to see if this trial is right for you.